NO20023266D0 - Antistoffer mot humant IL-1 - Google Patents

Antistoffer mot humant IL-1

Info

Publication number
NO20023266D0
NO20023266D0 NO20023266A NO20023266A NO20023266D0 NO 20023266 D0 NO20023266 D0 NO 20023266D0 NO 20023266 A NO20023266 A NO 20023266A NO 20023266 A NO20023266 A NO 20023266A NO 20023266 D0 NO20023266 D0 NO 20023266D0
Authority
NO
Norway
Prior art keywords
antibodies
human
Prior art date
Application number
NO20023266A
Other languages
English (en)
Other versions
NO329816B1 (no
NO20023266L (no
Inventor
Hermann Gram
Franco E Di Padova
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20023266(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20023266D0 publication Critical patent/NO20023266D0/no
Publication of NO20023266L publication Critical patent/NO20023266L/no
Publication of NO329816B1 publication Critical patent/NO329816B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
NO20023266A 2000-01-21 2002-07-05 Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning NO329816B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta

Publications (3)

Publication Number Publication Date
NO20023266D0 true NO20023266D0 (no) 2002-07-05
NO20023266L NO20023266L (no) 2002-08-28
NO329816B1 NO329816B1 (no) 2010-12-27

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023266A NO329816B1 (no) 2000-01-21 2002-07-05 Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning

Country Status (33)

Country Link
US (4) US20030124617A1 (no)
EP (1) EP1248804B2 (no)
JP (2) JP3978338B2 (no)
KR (1) KR100697126B1 (no)
CN (1) CN1395581B (no)
AR (1) AR027253A1 (no)
AT (1) ATE346868T1 (no)
AU (1) AU772949B2 (no)
BR (1) BR0107661A (no)
CA (1) CA2396212C (no)
CO (1) CO5261584A1 (no)
CY (1) CY1107989T1 (no)
CZ (1) CZ302738B6 (no)
DE (1) DE60124863T3 (no)
DK (1) DK1248804T4 (no)
ES (1) ES2274865T5 (no)
GB (1) GB0001448D0 (no)
HK (1) HK1050013A1 (no)
HU (1) HUP0204156A3 (no)
IL (2) IL150551A0 (no)
MX (1) MXPA02007091A (no)
MY (1) MY155269A (no)
NO (1) NO329816B1 (no)
NZ (1) NZ519936A (no)
PE (1) PE20011219A1 (no)
PL (1) PL207642B1 (no)
PT (1) PT1248804E (no)
RU (1) RU2264413C2 (no)
SI (1) SI1248804T2 (no)
SK (1) SK288054B6 (no)
TR (1) TR200201780T2 (no)
WO (1) WO2001053353A2 (no)
ZA (1) ZA200205659B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
KR20080074231A (ko) 2000-06-29 2008-08-12 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 및 사용 방법
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
EP1664796B1 (en) * 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
EP1766093B1 (en) 2004-02-06 2011-06-15 University of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
PL1899378T3 (pl) * 2005-06-21 2011-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
EP3332807B1 (en) * 2005-10-26 2023-02-22 Novartis AG Use of anti il-1beta antibodies
MX2008008621A (es) * 2005-12-29 2008-11-27 Centocor Inc Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
WO2007120828A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
EP2114443A4 (en) * 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
NZ579297A (en) 2007-02-28 2012-03-30 Schering Corp Combination therapy comprising an il-23 antagonist and a cytokine antagonist for treatment of immune disorders
RU2009148597A (ru) * 2007-05-29 2011-07-10 Новартис АГ (CH) Новые показания к применению при лечении антителами против il-1-бета
WO2009086003A1 (en) * 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
ES2398693T3 (es) * 2008-06-06 2013-03-21 Xoma Technology Ltd. Métodos para el tratamiento de la artritis reumatoide
EP2341935A4 (en) 2008-09-05 2012-07-25 Xoma Technology Ltd METHODS FOR IMPROVING BETA CELL FUNCTION
BR112012009828B8 (pt) 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
JP5904645B2 (ja) 2010-05-07 2016-04-13 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー ＩＬ−１β関連病態の治療のための方法
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
NZ707327A (en) 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
RU2013115927A (ru) * 2010-09-10 2014-10-20 Апексиджен, Инк. АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
DK2550363T3 (en) 2011-02-25 2015-03-23 Regeneron Pharma ADAM6 mice
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
MX356429B (es) 2011-12-20 2018-05-29 Regeneron Pharma Ratones con cadena ligera humanizada.
DK2814843T3 (da) 2012-02-13 2020-06-22 Agency Science Tech & Res IL-ß-NEUTRALISERENDE HUMANE MONOKLONALE ANTISTOFFER
LT3597037T (lt) 2012-06-12 2021-06-10 Regeneron Pharmaceuticals, Inc. Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
SK10352002A3 (sk) 2003-03-04
US20030124617A1 (en) 2003-07-03
JP2003520595A (ja) 2003-07-08
NZ519936A (en) 2004-02-27
EP1248804A2 (en) 2002-10-16
ZA200205659B (en) 2003-12-31
NO329816B1 (no) 2010-12-27
HUP0204156A3 (en) 2005-09-28
CY1107989T1 (el) 2013-09-04
SI1248804T1 (sl) 2007-06-30
PL207642B1 (pl) 2011-01-31
CA2396212A1 (en) 2001-07-26
WO2001053353A2 (en) 2001-07-26
BR0107661A (pt) 2002-11-19
DE60124863T2 (de) 2007-04-26
PL356297A1 (en) 2004-06-28
KR20020073178A (ko) 2002-09-19
DE60124863T3 (de) 2010-05-20
ES2274865T5 (es) 2010-04-19
CO5261584A1 (es) 2003-03-31
CZ20022531A3 (cs) 2002-10-16
NO20023266L (no) 2002-08-28
US20060251660A1 (en) 2006-11-09
SI1248804T2 (sl) 2010-04-30
CA2396212C (en) 2013-04-02
JP2007097598A (ja) 2007-04-19
ES2274865T3 (es) 2007-06-01
TR200201780T2 (tr) 2003-01-21
HUP0204156A2 (hu) 2003-03-28
US7491392B2 (en) 2009-02-17
AR027253A1 (es) 2003-03-19
ATE346868T1 (de) 2006-12-15
US20110182894A1 (en) 2011-07-28
EP1248804B2 (en) 2009-12-02
AU772949B2 (en) 2004-05-13
CN1395581A (zh) 2003-02-05
MXPA02007091A (es) 2002-12-13
IL150551A0 (en) 2003-02-12
DK1248804T4 (da) 2010-04-06
CN1395581B (zh) 2010-10-13
AU3369701A (en) 2001-07-31
WO2001053353A3 (en) 2002-04-04
US20090232803A1 (en) 2009-09-17
PE20011219A1 (es) 2001-12-17
KR100697126B1 (ko) 2007-03-20
IL150551A (en) 2010-11-30
DK1248804T3 (da) 2007-02-26
RU2264413C2 (ru) 2005-11-20
MY155269A (en) 2015-09-30
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
HK1050013A1 (zh) 2003-06-06
GB0001448D0 (en) 2000-03-08
RU2002121649A (ru) 2004-03-10
EP1248804B1 (en) 2006-11-29
JP3978338B2 (ja) 2007-09-19
PT1248804E (pt) 2007-02-28
SK288054B6 (sk) 2013-03-01

Similar Documents

Publication Publication Date Title
NO20023266D0 (no) Antistoffer mot humant IL-1
NO20030827L (no) Antistoffer mot human IL-1<beta>
NO20026063L (no) Antistoffer mot human MCP-1
NO20042388L (no) Antistoff mot CD40
NO20034554D0 (no) Antistoffer mot VLA-1
NO20041018L (no) Antistoffer mot OPGL
NO20004133D0 (no) Antistoffer mot human CD40
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
NO20013926D0 (no) Undersjoisk intervensjon
DE50106490D1 (de) Einschichtiger Hochleistungskatalysator
CY2012003I1 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
NO20041802L (no) Antistoffer mot human vevsfaktor
DE60125714D1 (de) Honigwabenstruktur
DE60142328D1 (de) Programmbereitstellungsvorrichtung
DK1857105T3 (da) Kathartisk præparat
DK1049717T3 (da) Antistoffer mod human IL-2
AT500208B8 (de) Turbolader
DE50108296D1 (de) Abgasturbolader
NO20030745L (no) Pseudomyciner effektive mot plantesykdommer
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
DK200000305U3 (da) Ultralydapparat
FI20002551A0 (fi) Voimalaite
DE50104457D1 (de) Zahnrad
EE200300377A (et) Loomulikud HI-viiruse vastased antikehad
ATA19892000A (de) Abgasturbolader

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees